Article Text

PDF

Adalimumab in severe and acute sciatica
  1. S Genevay,
  2. S Viatte,
  3. A Finckh,
  4. P Zufferey,
  5. F Balagué,
  6. C Gabay
  1. University of Geneva, Geneva, Switzerland

Statistics from Altmetric.com

Background

Based on several experimental results and on a preliminary study, a trial was undertaken to assess the efficacy of adalimumab, a tumour necrosis factor (TNF)α inhibitor, in patients with radicular pain due to lumbar disc herniation.

Methods

A multicentre randomised double-blind controlled trial was conducted between May 2005 and December 2007 in Switzerland. Patients with acute (<12 weeks) and severe (Oswestry disability index >50) radicular leg pain and imaging-confirmed lumbar disc herniation were randomised to receive as adjuvant therapy either two subcutaneous injections of adalimumab (40 mg) at 7-day interval or matching placebo. The primary outcome was leg pain, which was recorded every day for 10 days and at 6 weeks and 6 months based on a visual analogue scale (0–100).

Results

Of the 265 patients screened, 61 were enrolled (adalimumab=1) and 4 were lost to follow-up. Over time, leg pain decreased to a significantly greater extent in the adalimumab group than in the placebo group (p<0.001), but the effect size was relatively small (13.8 (95% CI −11.5 to 39.0) at 6 months). In addition, in the adalimumab group twice as many patients fulfilled the criteria for ‘responders’ and for ‘low residual disease impact’ (p<0.05) and fewer surgical discectomies were performed (6 vs 13, p=0.04).

Conclusion

The addition of a short course of adalimumab to the treatment regimen of patients with acute and severe sciatica resulted in a small decrease in leg pain and in significantly fewer surgical procedures.

Comments

This study is now accepted for publication in A&R.

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.